Mizuho analyst Mara Goldstein lowered the firm’s price target on Leap Therapeutics to $12 from $20 and keeps a Buy rating on the shares. The analyst cites expectations of higher dilution in 2024 based on the current share price valuation for the target drop. The firm’s expectations for equity capital sales in 2024 now include more shares issued due to the current depressed share price valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LPTX:
- Leap Therapeutics price target lowered to $11 from $20 at Baird
- Leap Therapeutics reports Q3 EPS (51c), consensus (58c)
- Leap Therapeutics Reports Third Quarter 2023 Financial Results
- Biotech Alert: Searches spiking for these stocks today
- These 2 “Strong Buy” Penny Stocks Could Gain Over 500%, Says Baird
